We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
-7.05%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.34B
AUM Growth
+$132M
Cap. Flow
+$289M
Cap. Flow %
21.59%
Top 10 Hldgs %
54.87%
Holding
79
New
21
Increased
28
Reduced
5
Closed
19

Top Buys

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$72.2M
2
EXAS
Exact Sciences
EXAS
+$45.4M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$44M
4
JANX icon
Janux Therapeutics
JANX
+$34M
5
ACLX
Arcellx
ACLX
+$31.3M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$97.9M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$52.3M
3
AZN icon
AstraZeneca
AZN
+$27.1M
4
NARI
Inari Medical, Inc. Common Stock
NARI
+$19.9M
5
ARGX icon
argenx
ARGX
+$19.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JAZZ icon
1
Jazz Pharmaceuticals
JAZZ
$16.1B
$160M 11.94%
1,500,000
+400,000
+36% +$44M
CYTK icon
2
Cytokinetics
CYTK
$10.8B
$112M 8.38%
2,075,000
-75,000
-3% -$4.53M
ASND icon
3
Ascendis Pharma A/S
ASND
$16.7B
$102M 7.63%
750,000
+225,000
+43% +$30.6M
RARE icon
4
Ultragenyx Pharmaceutical
RARE
$2.56B
$74M 5.52%
1,800,000
+1,690,000
+1,536% +$72.2M
GMED icon
5
Globus Medical
GMED
$10.9B
$61.6M 4.6%
900,000
-100,000
-10% -$5.97M
INSM icon
6
Insmed
INSM
$22.6B
$50.3M 3.75%
750,000
– –
ONC
7
BeOne Medicines Ltd
ONC
$34.3B
$49.9M 3.72%
350,000
+25,000
+8% +$3.85M
SLNO
8
DELISTED
Soleno Therapeutics
SLNO
$49M 3.65%
1,200,000
-50,000
-4% -$2.12M
EXAS
9
DELISTED
Exact Sciences
EXAS
$39.1M 2.91%
925,000
+825,000
+825% +$45.4M
ACLX
10
DELISTED
Arcellx
ACLX
$37.3M 2.78%
675,000
+575,000
+575% +$31.3M
IMTX icon
11
Immatics
IMTX
$1.19B
$32M 2.38%
2,750,000
+1,550,000
+129% +$17.5M
JANX icon
12
Janux Therapeutics
JANX
$915M
$30.4M 2.26%
+725,000
New +$34M
ATXS
13
DELISTED
Astria Therapeutics
ATXS
$29.6M 2.21%
3,250,000
+2,150,000
+195% +$21M
KALV
14
DELISTED
KalVista Pharmaceuticals
KALV
$27.1M 2.02%
2,300,000
+1,645,000
+251% +$19.2M
SVRA icon
15
Savara
SVRA
$1.09B
$26.2M 1.95%
+6,490,000
New +$28.9M
ITOS
16
DELISTED
iTeos Therapeutics
ITOS
$26M 1.94%
+1,750,000
New +$25.1M
APLT
17
DELISTED
Applied Therapeutics
APLT
$25.4M 1.89%
5,430,000
+320,000
+6% +$1.51M
AXSM icon
18
Axsome Therapeutics
AXSM
$12.1B
$24.1M 1.8%
+300,000
New +$22.2M
GPCR icon
19
Structure Therapeutics
GPCR
$3.4B
$22M 1.64%
+560,000
New +$23M
LQDA icon
20
Liquidia Corp
LQDA
$7.72B
$22M 1.64%
1,830,000
-170,000
-9% -$2.26M
ALXO icon
21
ALX Oncology
ALXO
$268M
$21.7M 1.62%
3,600,000
+990,000
+38% +$12.2M
QURE icon
22
uniQure
QURE
$2.52B
$21.3M 1.59%
4,750,000
+25,000
+0.5% +$122K
BMY icon
23
Bristol-Myers Squibb
BMY
$130B
$20.8M 1.55%
+500,000
New +$22.4M
XENE icon
24
Xenon Pharmaceuticals
XENE
$6.28B
$20.5M 1.53%
525,000
+125,000
+31% +$5M
PRAX icon
25
Praxis Precision Medicines
PRAX
$8.25B
$18.2M 1.36%
440,000
+230,000
+110% +$10.9M
1
2 3 4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Vestal Point Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Vestal Point Capital held 79 positions worth $1.34B, up 11% from $1.21B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Vestal Point Capital deployed $289M of net new capital in Q2 2024, opening 21 new positions and adding to 28 existing holdings. Its largest new stake was Janux Therapeutics: 725,000 shares worth $30.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Inari Medical, Inc. Common Stock, an estimated $19.9M trimmed.

  • Vestal Point Capital's largest Q2 2024 buy was Janux Therapeutics: 725,000 shares worth $30.4M.
  • Vestal Point Capital added most to Ultragenyx Pharmaceutical in Q2 2024, an estimated $72.2M increase.
  • Vestal Point Capital's biggest Q2 2024 reduction was Inari Medical, Inc. Common Stock, cutting an estimated $19.9M.
  • Vestal Point Capital fully exited Neurocrine Biosciences in Q2 2024, selling an estimated $97.9M.
  • Vestal Point Capital's ten largest holdings make up 55% of its $1.34B portfolio in Q2 2024.
  • Vestal Point Capital opened 21 new positions and closed 19 in Q2 2024.
  • Vestal Point Capital's portfolio value rose 11% quarter-over-quarter to $1.34B.

Based on Vestal Point Capital's 13F filing for Q2 2024, filed 14 Aug 2024.